EP0474727B1
(de)
*
|
1989-05-19 |
1997-07-23 |
Genentech, Inc. |
Her2 extrazellulare domäne
|
US5183884A
(en)
*
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US5578482A
(en)
*
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US5776755A
(en)
*
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
US6107046A
(en)
*
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
US5811098A
(en)
*
|
1992-11-24 |
1998-09-22 |
Bristol-Myers Squibb Company |
Antibodies to HER4, human receptor tyrosine kinase
|
WO1995002057A1
(en)
*
|
1993-07-09 |
1995-01-19 |
The Institute Of Cancer Research |
Protein tyrosine kinase and ligands thereof
|
DK1650303T3
(da)
*
|
1993-10-27 |
2008-09-08 |
Univ Columbia |
Fremgangsmåde til generering af et subtraheret cDNA-bibliotek og anvendelse af det genererede bibliotek
|
US5518885A
(en)
*
|
1994-04-19 |
1996-05-21 |
The United States Of America As Represented By The Department Of Health & Human Services |
ERBB2 promoter binding protein in neoplastic disease
|
US7175995B1
(en)
|
1994-10-27 |
2007-02-13 |
Thomas Jefferson University |
TCL-1 protein and related methods
|
US5985598A
(en)
*
|
1994-10-27 |
1999-11-16 |
Thomas Jefferson University |
TCL-1 gene and protein and related methods and compositions
|
US5635351A
(en)
*
|
1995-03-14 |
1997-06-03 |
The Regents Of The University Of California |
Genetic gain and loss in gliomas
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
WO1997035885A1
(en)
*
|
1996-03-27 |
1997-10-02 |
Genentech, Inc. |
ErbB3 ANTIBODIES
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
AU727606B2
(en)
*
|
1996-07-12 |
2000-12-14 |
Genentech Inc. |
Gamma-heregulin
|
DK0912734T3
(da)
|
1996-07-12 |
2011-02-07 |
Genentech Inc |
Kimæriske heteromultimer-adhæsiner
|
US5710137A
(en)
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US6136558A
(en)
*
|
1997-02-10 |
2000-10-24 |
Genentech, Inc. |
Heregulin variants
|
ATE427353T1
(de)
*
|
1997-02-10 |
2009-04-15 |
Genentech Inc |
Heregulin varianten
|
AU7267398A
(en)
*
|
1997-04-30 |
1998-11-24 |
Hans Klingemann |
Natural killer cell lines and methods of use
|
US7052692B1
(en)
|
1997-09-02 |
2006-05-30 |
Advanced Research & Technology Institute |
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
|
CA2306450C
(en)
|
1997-10-29 |
2012-07-10 |
Genentech, Inc. |
Polypeptides and nucleic acids encoding same
|
IL135704A
(en)
|
1997-10-29 |
2008-04-13 |
Genentech Inc |
Method for the diagnosis of cancerous growth of cells by identifying the secreted polypeptide WISP-1 affected by WNT-1
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
*
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
DE69942981D1
(de)
*
|
1998-10-09 |
2011-01-05 |
Vegenics Ltd |
Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
|
EP1165113B1
(de)
*
|
1999-04-06 |
2008-06-11 |
Genentech, Inc. |
Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
DK1189634T3
(da)
*
|
1999-06-25 |
2007-06-25 |
Genentech Inc |
Behandling af prostatacancer med anti-ErbB2-antistoffer
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
AU784045B2
(en)
|
1999-06-25 |
2006-01-19 |
Genentech Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
BRPI0012196B8
(pt)
|
1999-06-25 |
2021-05-25 |
Genentech Inc |
artigo industrializado
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
KR20110008112A
(ko)
|
1999-08-27 |
2011-01-25 |
제넨테크, 인크. |
항-ErbB2 항체 투여 치료 방법
|
US7390632B2
(en)
*
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
DK1282443T3
(da)
|
2000-05-19 |
2010-01-04 |
Genentech Inc |
Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi
|
CN1204142C
(zh)
*
|
2000-06-01 |
2005-06-01 |
冯宝章 |
反基因V-erbB寡核苷酸及其应用
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
WO2002039121A2
(en)
*
|
2000-11-03 |
2002-05-16 |
Board Of Regents, The University Of Texas System |
Methods for detecting the efficacy of anticancer treatments
|
CN1494552A
(zh)
|
2001-01-19 |
2004-05-05 |
·��ά��֢�о�Ժ |
Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
|
EP1228766A1
(de)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion
|
JP4398644B2
(ja)
*
|
2001-04-06 |
2010-01-13 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア |
ErbB界面ペプチド擬態およびその使用方法
|
WO2002088363A2
(en)
*
|
2001-05-02 |
2002-11-07 |
Bayer Healthcare Ag |
Regulation of novel human prolyl 4-hydroxylases
|
US7638302B2
(en)
*
|
2001-05-31 |
2009-12-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
DE10131187C2
(de)
*
|
2001-06-28 |
2003-06-18 |
Infineon Technologies Ag |
Belichtungsmaske mit reparierter Blindstruktur
|
US7125680B2
(en)
*
|
2001-07-27 |
2006-10-24 |
The Regents Of The University Of California |
Methods and materials for characterizing and modulating interaction between heregulin and HER3
|
EP1283053A1
(de)
*
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitore der HER3 Aktivität
|
CA2459137A1
(en)
*
|
2001-09-14 |
2003-03-27 |
Incyte Genomics, Inc. |
Receptors and membrane-associated proteins
|
JP2003110360A
(ja)
*
|
2001-09-28 |
2003-04-11 |
Seiko Epson Corp |
電圧制御型発振器、受信装置および通信装置
|
CA2480099C
(en)
*
|
2002-03-26 |
2019-01-08 |
Zensun (Shanghai) Sci-Tech. Ltd. |
Erbb3 based methods and compositions for treating neoplasms
|
US20040229380A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US20040229294A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
US7402397B2
(en)
|
2002-05-21 |
2008-07-22 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
AU2003233662B2
(en)
|
2002-05-23 |
2010-04-01 |
Trustees Of The University Of Pennsylvania |
Fas peptide mimetics and uses thereof
|
CN101711866A
(zh)
|
2002-07-15 |
2010-05-26 |
健泰科生物技术公司 |
鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
EP1572972A4
(de)
*
|
2002-11-21 |
2007-11-21 |
Genentech Inc |
Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
|
EP1613205B1
(de)
|
2003-04-01 |
2013-04-24 |
Monogram BioSciences, Inc. |
Erbb-oberflächen-rezeptor-komplexe als biomarker
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
JP2007525187A
(ja)
*
|
2003-05-16 |
2007-09-06 |
レセプター・バイオロジクス・インコーポレイテッド |
イントロン融合タンパク質、ならびにその同定方法および使用方法
|
US7402398B2
(en)
*
|
2003-07-17 |
2008-07-22 |
Monogram Biosciences, Inc. |
Measuring receptor homodimerization
|
AU2004267420A1
(en)
*
|
2003-08-11 |
2005-03-03 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
EP1681983A4
(de)
*
|
2003-10-14 |
2008-12-10 |
Monogram Biosciences Inc |
Rezeptor-tyrosin-kinase-signalpfad-analyse für diagnose und therapie
|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20060034840A1
(en)
*
|
2004-04-08 |
2006-02-16 |
Agus David B |
ErbB antagonists for pain therapy
|
JP2008506366A
(ja)
*
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
CN102973947A
(zh)
|
2004-06-01 |
2013-03-20 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
RU2361880C2
(ru)
|
2004-07-22 |
2009-07-20 |
Дженентек, Инк. |
Композиция антител к her2
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7939267B2
(en)
*
|
2004-11-04 |
2011-05-10 |
Laboratory Corporation Of America Holdings |
Detection of activation of endothelial cells as surrogate marker for angiogenesis
|
CN101115849A
(zh)
*
|
2004-12-07 |
2008-01-30 |
健泰科生物技术公司 |
选择her抑制剂疗法的患者
|
RU2438705C2
(ru)
|
2005-01-21 |
2012-01-10 |
Дженентек, Инк. |
Введение фиксированных доз her-антител
|
US20060177448A1
(en)
*
|
2005-02-09 |
2006-08-10 |
Genentech, Inc. |
Inhibiting HER2 shedding with matrix metalloprotease antagonists
|
NZ590431A
(en)
|
2005-02-23 |
2012-08-31 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
JP5638804B2
(ja)
|
2006-08-04 |
2014-12-10 |
アストラゼネカ アクチボラグ |
ErbB2に対する抗体
|
US20100047829A1
(en)
*
|
2006-11-28 |
2010-02-25 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
EP2716301B1
(de)
|
2007-02-16 |
2017-04-05 |
Merrimack Pharmaceuticals, Inc. |
Antikörper gegen erbb3 und verwendungen davon
|
NZ578824A
(en)
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
CN101679974B
(zh)
|
2007-03-27 |
2015-09-30 |
航道生物技术有限责任公司 |
包含抗体替代轻链序列的构建体和文库
|
DK2171090T3
(da)
|
2007-06-08 |
2013-06-10 |
Genentech Inc |
Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
|
CA2706763C
(en)
*
|
2007-11-27 |
2013-07-30 |
Laboratory Corporation Of America Holdings |
Enhanced method for detecting and/or quantifying an analyte in a sample
|
EP2235536A4
(de)
*
|
2007-12-20 |
2011-05-04 |
Lab Corp America Holdings |
Her-2-diagnoseverfahren
|
DK3012251T3
(en)
|
2008-01-18 |
2017-10-09 |
Natco Pharma Ltd |
PROCEDURE FOR PREPARATION 6,7-DIALCOXY-QUINAZOLINE DERIVATIVES
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
US8663643B2
(en)
|
2008-03-18 |
2014-03-04 |
Genentech, Inc. |
Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
WO2009157919A1
(en)
*
|
2008-06-23 |
2009-12-30 |
Tumor Biology Investment Group, Inc. |
SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
|
CN102224255A
(zh)
*
|
2008-08-15 |
2011-10-19 |
梅里麦克制药股份有限公司 |
用于预测细胞对治疗剂的应答的方法和系统
|
WO2010065568A2
(en)
|
2008-12-01 |
2010-06-10 |
Laboratory Corporation Of America Holdings |
METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
|
US8349574B2
(en)
*
|
2009-01-15 |
2013-01-08 |
Laboratory Corporation Of America Holdings |
Methods of determining patient response by measurement of Her-3
|
PE20120539A1
(es)
*
|
2009-03-20 |
2012-05-12 |
Genentech Inc |
Anticuerpos anti-her biespecifico
|
AU2010242914B2
(en)
|
2009-04-29 |
2014-11-13 |
Trellis Bioscience, Llc |
Improved antibodies immunoreactive with heregulin-coupled HER3
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
SG10201507044PA
(en)
|
2009-05-29 |
2015-10-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US9050341B2
(en)
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
EP2488199A1
(de)
|
2009-10-14 |
2012-08-22 |
Merrimack Pharmaceuticals, Inc. |
Auf igf-1r- und erbb3-signalisierung gerichtete bispezfische bindemittel und ihre verwendung
|
MX349513B
(es)
|
2009-11-13 |
2017-08-02 |
Amgen Inc * |
Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
|
US10584181B2
(en)
|
2009-12-04 |
2020-03-10 |
Genentech, Inc. |
Methods of making and using multispecific antibody panels and antibody analog panels
|
HUE029026T2
(en)
|
2009-12-22 |
2017-01-30 |
Roche Glycart Ag |
Anti-HER3 antibodies and their applications
|
ES2535503T3
(es)
|
2010-03-11 |
2015-05-12 |
Merrimack Pharmaceuticals, Inc. |
Uso de inhibidores de ErbB3 en el tratamiento del cáncer de mama triple negativo
|
BR112012025730B1
(pt)
|
2010-04-09 |
2020-12-08 |
Aveo Pharmaceuticals, Inc |
anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US8741288B2
(en)
*
|
2010-07-07 |
2014-06-03 |
Chang Gung Medical Foundation, Linkou Branch |
Protein markers for detecting liver cancer and method for identifying the markers thereof
|
MY162825A
(en)
|
2010-08-20 |
2017-07-31 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
EA201300996A1
(ru)
|
2011-03-11 |
2014-01-30 |
Мерримак Фармасьютикалс, Инк. |
Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы
|
CA2833643A1
(en)
|
2011-04-19 |
2012-10-26 |
Merrimack Pharmaceuticals, Inc. |
Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
|
WO2012156309A1
(en)
|
2011-05-13 |
2012-11-22 |
Millegen |
Antibodies against her3
|
SG194609A1
(en)
|
2011-05-19 |
2013-12-30 |
Lab Corp America Holdings |
Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
|
WO2012176779A1
(ja)
|
2011-06-20 |
2012-12-27 |
協和発酵キリン株式会社 |
抗erbB3抗体
|
WO2013016714A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
MX2014002436A
(es)
|
2011-08-31 |
2014-05-27 |
Genentech Inc |
Marcadores de diagnostico.
|
KR20140069331A
(ko)
|
2011-09-30 |
2014-06-09 |
리제너론 파아마슈티컬스, 인크. |
항-ErbB3 항체 및 이의 용도
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
EP3974832A1
(de)
|
2011-10-06 |
2022-03-30 |
Aveo Pharmaceuticals, Inc. |
Vorhersage einer tumorreaktion auf anti-erbb3-antikörper
|
CN109908341B
(zh)
|
2011-10-14 |
2023-06-27 |
霍夫曼-拉罗奇有限公司 |
Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
|
KR102080535B1
(ko)
|
2011-11-23 |
2020-02-24 |
메디뮨 엘엘씨 |
Her3에 특이적인 결합 분자 및 이의 용도
|
MX2014006529A
(es)
|
2011-11-30 |
2014-11-25 |
Genentech Inc |
Mutaciones de erbb3 en cancer.
|
KR102151383B1
(ko)
|
2011-12-05 |
2020-09-03 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
EP2788500A1
(de)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identifizierung von non-respondern auf her2-inhibitoren
|
ES2710916T3
(es)
|
2011-12-22 |
2019-04-29 |
I2 Pharmaceuticals Inc |
Proteínas de unión sustitutas
|
IN2014KN01772A
(de)
|
2012-02-23 |
2015-10-23 |
U3 Pharma Gmbh |
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
WO2013152034A1
(en)
|
2012-04-02 |
2013-10-10 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
EP2954068B8
(de)
|
2013-02-05 |
2018-10-31 |
Pierian Holdings, Inc. |
Wirkstoffauswahl für eine therapie gegen nicht-kleinzelligen lungenkrebs
|
SG11201505940WA
(en)
|
2013-02-18 |
2015-08-28 |
Vegenics Pty Ltd |
Ligand binding molecules and uses thereof
|
CA2908515A1
(en)
|
2013-04-05 |
2014-10-09 |
Laboratory Corporation Of America Holdings |
Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
|
EP2994164B1
(de)
|
2013-05-08 |
2020-08-05 |
Zymeworks Inc. |
Bispezifische her2- und her3-antigenbindende konstrukte
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
EP3087394A2
(de)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
IL300540A
(en)
|
2014-04-10 |
2023-04-01 |
Daiichi Sankyo Co Ltd |
Preparation method for drug conjugates - antibody against - HER3
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
EP3539990B1
(de)
|
2014-07-16 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
Her3-inhibition bei serösem low-grade ovarialkarzinom
|
CA2955456A1
(en)
|
2014-07-17 |
2016-01-21 |
Brian J. Czerniecki |
Identification of immunogenic mhc class ii peptides for immune-based therapy
|
US10689459B2
(en)
|
2014-12-12 |
2020-06-23 |
Novartis Ag |
Treatment of breast cancer brain metastases
|
US20180169230A1
(en)
|
2015-05-29 |
2018-06-21 |
Merrimack Pharmaceuticals, Inc. |
Combination cancer therapies
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
EP4180455A1
(de)
|
2015-06-29 |
2023-05-17 |
Daiichi Sankyo Company, Limited |
Verfahren zur selektiven herstellung eines antikörper-wirkstoff-konjugats
|
JP2018527286A
(ja)
*
|
2015-07-17 |
2018-09-20 |
ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. |
免疫に基づく療法のための、免疫原性mhcクラスiiペプチドの同定
|
WO2017127545A1
(en)
|
2016-01-19 |
2017-07-27 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
|
CN109310754A
(zh)
|
2016-03-15 |
2019-02-05 |
梅里麦克制药股份有限公司 |
使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
JPWO2018110515A1
(ja)
|
2016-12-12 |
2019-10-24 |
第一三共株式会社 |
抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
EP3562844A1
(de)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Behandlung von fortgeschrittenem her2-exprimierendem krebs
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
|
CN115089704A
(zh)
|
2017-01-17 |
2022-09-23 |
基因泰克公司 |
皮下her2抗体配制剂
|
HRP20240069T1
(hr)
|
2017-03-02 |
2024-03-29 |
Genentech, Inc. |
Adjuvantno liječenje her2-pozitivnog raka dojke
|
TW201902509A
(zh)
|
2017-04-24 |
2019-01-16 |
美商建南德克公司 |
Erbb2/her2突變
|
TW202330036A
(zh)
|
2017-05-15 |
2023-08-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
WO2018223103A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving her antigens
|
KR20200041993A
(ko)
|
2017-08-31 |
2020-04-22 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
TW202402806A
(zh)
|
2018-05-18 |
2024-01-16 |
日商第一三共股份有限公司 |
抗muc1抗體藥物複合體
|
EP4171748A1
(de)
|
2020-06-29 |
2023-05-03 |
Genentech, Inc. |
Kombination aus pertuzumab und trastuzumab mit fester dosis
|
EP4180061A1
(de)
|
2021-11-10 |
2023-05-17 |
Nerviano Medical Sciences S.r.l. |
Linker-reagenzien für anthracyclinderivate, antikörper-arznemittelkonjugate und verfahren
|